Viridian Therapeutics, Inc.\DE (VRDN) Cash from Investing Activities (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at $77.3 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 22.79% year-over-year to $77.3 million in Q1 2026; TTM through Mar 2026 was -$60.4 million, a 517.57% decrease from a year earlier, with the FY2025 full-year figure at -$37.6 million, up 83.57% from the prior year.
• Cash from Investing Activities rose to $77.3 million in Q1 2026 per VRDN's latest filing, from -$339.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $126.1 million in Q3 2025 and bottomed at -$339.4 million in Q4 2025.
• The 5-year median for Cash from Investing Activities is $14.0 million (2022), against an average of -$23.4 million.
• Across the five-year window, Cash from Investing Activities soared 582.31% in 2022 and sank 975.93% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$180.6 million in 2022, then climbed by 6.03% to -$169.7 million in 2023, then soared by 62.93% to -$62.9 million in 2024, then tumbled by 439.49% to -$339.4 million in 2025, then surged by 122.76% to $77.3 million in 2026.
• Per Business Quant, the three latest VRDN Cash from Investing Activities figures stand at $77.3 million (Q1 2026), -$339.4 million (Q4 2025), and $126.1 million (Q3 2025).